Results 231 to 240 of about 58,715 (292)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 12, Page 1673-1684, June 2026.
We conducted a nationwide, multicenter cohort study using a target trial emulation framework to compare baclofen and acamprosate in patients with compensated alcohol‐associated cirrhosis. After matching, baclofen initiation was associated with a higher 1‐year risk of major adverse liver outcomes, driven primarily by hepatic encephalopathy, particularly
Yee Hui Yeo, Sepideh Mehravar, Ellen Choi, Ju Dong Yang, Hyun‐Seok Kim, Yun Wang, Aarshi Vipani, Hirsh D. Trivedi, Walid Ayoub, Parnian Naji, Alexander Kuo, Chun‐Ying Wu, Lorenzo Leggio, Juan Pablo Arab   +13 more
wiley   +1 more source

Risk factors for hepatic encephalopathy in patients following transjugular intrahepatic portosystemic shunt: a meta-analysis and systematic review. [PDF]

BMC Surg
Hu W, Qin J, Qiang L, Zhang Y.
europepmc   +1 more source

Association of GLP‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4837-4846, June 2026.
ABSTRACT Aims To evaluate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation and the risk of hepatic decompensation compared with dipeptidyl peptidase 4 inhibitors (DPP4is) in a racially and ethnically diverse cohort of adults with Type 2 diabetes.
Inyoung Hwang, Yun Kim, Sang Won Lee
wiley   +1 more source

Risk factors for pneumonia, hepatic encephalopathy, and acute kidney injury in patients with hepatitis B virus-related acute-on-chronic liver failure. [PDF]

Front Med (Lausanne)
Wei L, Shi W, Yang X, Ma H, Wan H, Zhou X.   +5 more
europepmc   +1 more source

Proteomic Profiling of Plasma to Uncover Novel Intervention Targets and Prognostic Biomarkers for Chronic Liver Diseases

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5029-5042, June 2026.
ABSTRACT Aims The burden of chronic liver disease (CLD) is increasing. This study aims to identify protein markers for CLD and its progression, and develop a protein‐based risk prediction model. Materials and Methods We used proteome‐wide Mendelian randomization (MR), Bayesian colocalization and summary‐data‐based MR with proteomic data from deCODE ...
Xinxuan Li, Jing Sun, Jianhui Zhao, Fangyuan Jiang, Meng Zhang, Hao Wu, Shuai Yuan, Xue Li, Juan Lu, Christos S. Mantzoros   +9 more
wiley   +1 more source

Risk prediction models for hepatic encephalopathy following TIPS: a systematic review and meta-analysis. [PDF]

Front Med (Lausanne)
Fang Z, Liu Z, Pu Z, Xia Q, Zhang Q, Wang L, Jia P, Tang X.   +7 more
europepmc   +1 more source

Successful use of haemoperfusion therapy in an adult horse with hepatic encephalopathy and cholangiohepatitis

Equine Veterinary Education, Volume 38, Issue 6, Page e307-e314, June 2026.
Summary A 4‐year‐old, 520 kg, American Quarter Horse broodmare, approximately 90 days in foal, was presented to Texas A&M University Teaching Hospital for suspected liver disease. Based on clinicopathological values and hepatic abnormalities noted ultrasonographically, the mare was presumptively diagnosed with cholangiohepatitis.
A. C. Trimble, S. H. White‐Springer, S. Alpini, E. Rumfola, A. N. DiSilvestro, Y. Ueda, K. Hobbs   +6 more
wiley   +1 more source

Frailty Diagnosed With the Clinical Frailty Scale Stratifies the Risk of Covert and Overt Hepatic Encephalopathy in Patients With Cirrhosis. [PDF]

JGH Open
Unome S, Miwa T, Hirata S, Nakashima S, Nishimura K, Oi M, Aiba M, Imai K, Takai K, Shimizu M.   +9 more
europepmc   +1 more source

Prognostic Value of an Early Response to Tolvaptan and Its Clinical Implications in Patients With Cirrhosis and Hepatic Edema: A Nationwide Multicenter Cohort Study

Hepatology Research, Volume 56, Issue 6, Page 925-932, June 2026.
In a nationwide multicenter cohort, an early response to tolvaptan (≥ 1.5‐kg weight loss within 7 days) was independently associated with improved long‐term survival in patients with cirrhosis and hepatic edema. Early initiation before renal impairment or hyponatremia may optimize treatment response and prognosis. ABSTRACT Aim Hepatic edema indicates a
Kaori Koyano, Taeang Arai, Hidenori Toyoda, Keizo Kato, Joji Tani, Suguru Ogura, Tomomi Okubo, Korenobu Hayama, Norio Itokawa, Toshifumi Tada, Akito Nozaki, Atsushi Hiraoka, Kentaro Matsuura, Toru Ishikawa, Naoto Kawabe, Tsunamasa Watanabe, Koichi Takaguchi, Asahiro Morishita, Hironao Okubo, Motoh Iwasa, Hiroki Nishikawa, Yasuhito Tanaka, Masanori Atsukawa   +22 more
wiley   +1 more source

For Me, Quality of Life Is When I Get Through the Day Without Thinking: I Won't Make It: A Participatory Qualitative Study of Health‐Related Quality of Life in Rare Liver Diseases

Health Expectations, Volume 29, Issue 3, June 2026.
ABSTRACT Background Vascular liver diseases (VLDs) predominantly affect young adults and require lifelong monitoring. The health‐related quality of life (HRQoL) of patients with VLDs is deteriorated, with high levels of fatigue and depressive symptoms, but their lived experience and unmet needs remain unknown.
Anouck Alary, Jane Sattoe, Lynda Sifer, Isabelle Aujoulat, José Mira, Guenda Bernegger, Giada Danesi, Eva Gil‐Hernández, Pura Ballester, Mercedes Guilabert, Doortje Nipius, Jeanina Kousemaker‐Nieuwdorp, Kay van der Meer‐Kuiper, Stefania Cannavò, Cecile Drossart, Liliane Veniat, María Caiata Zufferey, Agnes Dumas   +17 more
wiley   +1 more source